MediWound Initiates Post-Marketing Study with NexoBrid® to Treat Severe Burns in Pediatric Patients
YAVNE,
The prospective, randomized, controlled, multicenter study will compare
NexoBrid with standard-of-care treatment in approximately 160 children
between the ages of 4 and 17 with severe burns. The study is currently
planned to be conducted in approximately 25 sites in
"We are focusing on advancing our business plan and are very happy to
initiate this pediatric study. The early assessment of burn severity in
children, who more frequently suffer from scalding liquid burns, is very
challenging, and treating children with the surgical standard-of-care is
even more demanding than surgically treating adults. More than 110
children have been recruited in our past clinical studies and the
clinical effects for those treated with NexoBrid in terms of earlier
eschar removal, reduction in surgical burden and long-term cosmesis and
function were even greater than in adults" stated
"Advancing burn care in general and in children in particular is a
highly motivating factor for us all. We strive to have NexoBrid
available to benefit these young burn victims and the initiation of the
PIP study is a big step toward that goal," added
About
Cautionary Note Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of
Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E
of the US Securities Exchange Act of 1934, as amended, and the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act
of 1995. Forward-looking statements are statements that are not
historical facts, such as statements regarding assumptions and results
related to financial results forecast, commercial results, clinical
trials and the regulatory authorizations. Forward-looking statements are
based on MediWound's current knowledge and its present beliefs and
expectations regarding possible future events and are subject to risks,
uncertainties and assumptions. Actual results and the timing of events
could differ materially from those anticipated in these forward-looking
statements as a result of several factors including, but not limited to,
unexpected results of clinical trials, delays or denial in the EMA
regulatory approval process or additional competition in the market. The
forward-looking statements made herein speak only as of the date of this
announcement and
CFO
ir@mediwound.co.il
or
LHA
Senior Vice President
afields@lhai.com
Source:
News Provided by Acquire Media